FOXC1 and diffuse large B-cell lymphoma: Despite these limitations, the observed improvement in prognostic accuracy with the inclusion of these markers highlights the promising potential of targeting FOXC1‐positive stromal cells and pERK1/2 tumor cells as innovative therapeutic strategies for treating recurrent and aggressive DLBCL.